GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (FRA:VIA) » Definitions » Sale Of Investment

Viatris (FRA:VIA) Sale Of Investment : €23 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Viatris Sale Of Investment?

Viatris's sale of investment for the three months ended in Mar. 2024 was €7 Mil. It means Viatris gained €7 Mil from selling investments. Viatris's sale of investment for the trailing twelve months (TTM) ended in Mar. 2024 was €23 Mil.

Compared with last quarter (€5 Mil in Dec. 2023 ), Viatris gained more money from selling investments in Mar. 2024 (€7 Mil).

Viatris Sale Of Investment Historical Data

The historical data trend for Viatris's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Sale Of Investment Chart

Viatris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.39 38.63 26.37 28.23 24.12

Viatris Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.41 7.02 4.03 4.95 7.08

Viatris Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viatris Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Viatris's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (FRA:VIA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (FRA:VIA) » Definitions » Sale Of Investment
Comparable Companies
NBIX CTLT ITCI ELAN LNTH PRGO ALKS ALVO PBH AMPH ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ SZSE:000538 HKSE:03692 TSE:4507
Traded in Other Exchanges
VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany MYL:Austria
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Website
https://www.viatris.com
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.